The reason I post less now is because I'm doing less research now, and actually I feel more confident about AT1. There are perhaps faster ways to make money, but I'm locked in until it rises. Short term it's annoying to be low but ( in my opinion only, DYOR ) it's just a matter of waiting. This sort of 2022 report is what I am making my judgements on,( 2022 report on Hub and spoke models of STI testing and treatment ) plus the amount of cash they have to burn.
The problem
The study ( 2020-2022
The result
Hub and spoke models have proven to be highly successful in these study, despite Covid, while testing rates outside of these 3 clinics went down. Atomo's rapid device will highly likely be a permanent part of this growing model, because A. The requirements for this type of rapid test are so onerous and such a big hurdle for competition. B. GP's can incorporate the model and workflow to expand their existing practice. C. The videos on youtube of doctors using Atomo's cartridge and commenting how much easier it is to use than other tests. That's my evidence. (You can invent a tricky device but it must have the support and place for it to fit smoothly into the workflow of ordinary practice. )
The requirements for blood are SO much higher, so now Atomo can build a menu of STI disease solutions.
The uptake may be slow. Evidence for a 50% increase in diagnosis for e-health has been around since 2015 but these things take time.
I'm less focused on the SP these days and want to see evidence for the business. There are a lot of shares outstanding. The business will need to grow on steady ground for more people to buy in, but the case looks very strong.
Plus the fact Covid is still out there. Dan Andrews has covid now and he found out using a rapid test.
If I were selling test contracts to blue chip company's I would be saying, and imagine they are saying, look, with China you can never be sure what will happen. We can guarantee supply at a similar price. So why worry?
With logistics and COG headwinds maybe will, maybe won't make massive profit but they will be able to help the company grow and survive, to give it's R and D team more time to cement it's place in overall areas including Covid. Can see them building their brand and they seem to be.
So, I worry less, and focus on other investments these days. Good luck to all holders, and feel free to disagree, because counter-points are useful for reflection. Changed to buy.
